COMPARATIVE EFFICACY OF AGNUS CASTUS AND LYCOPODIUM CLAVATUM IN THE HOMOEOPATHIC MANAGEMENT OF OLIGOSPERMIA
How to Cite This Article
Dr. Mandar Kapare, Dr. Abhishek P. Kulkarni, Dr. Vipul R. Shastri, Dr. Pankaj N. Lathiya (2026); COMPARATIVE EFFICACY OF AGNUS CASTUS AND LYCOPODIUM CLAVATUM IN THE HOMOEOPATHIC MANAGEMENT OF OLIGOSPERMIA, SRJ: INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 1 (10), 26-34, ISSN: 3139-8758. DOI URL: https://doi.org/10.68295/SRJ/NRHG1813
Abstract
Background: Oligozoospermia is a semen abnormality encountered during the assessment of Male Infertility. Agnus Castus and Lycopodium Clavatum appear in Homoeopathic prescribing literature, but prescribing frequency is distinct from evidence of treatment benefit.
Methods: A structured search and source-verification exercise considered scholarly reports on Homoeopathic interventions, Oligozoospermia, Semen outcomes and Male Infertility. Publicly verifiable original reports and clinical guidelines were critically examined. Extracted fields covered intervention assignment, participant number, comparator, semen analysis and reproductive outcomes. PRISMA 2020 reporting concepts informed the evidence audit; a complete database-export-based PRISMA enumeration could not be established.
Results: Five clinically relevant or contextual reports were inspected in detail: a 2024 mixed-sex observational survey with 15 male records, a 2025 non-peer-reviewed single-arm study involving 10 men, a 2002 uncontrolled pilot involving 45 men, a 2022 seven-couple case series and a 2022 single-patient case report.
Conclusion: The retrieved publications do not establish comparative clinical efficacy or superiority of either preparation for Oligozoospermia. Controlled, prospectively registered research with standardized semen analyses and reproductive outcomes is required.
Methods: A structured search and source-verification exercise considered scholarly reports on Homoeopathic interventions, Oligozoospermia, Semen outcomes and Male Infertility. Publicly verifiable original reports and clinical guidelines were critically examined. Extracted fields covered intervention assignment, participant number, comparator, semen analysis and reproductive outcomes. PRISMA 2020 reporting concepts informed the evidence audit; a complete database-export-based PRISMA enumeration could not be established.
Results: Five clinically relevant or contextual reports were inspected in detail: a 2024 mixed-sex observational survey with 15 male records, a 2025 non-peer-reviewed single-arm study involving 10 men, a 2002 uncontrolled pilot involving 45 men, a 2022 seven-couple case series and a 2022 single-patient case report.
Conclusion: The retrieved publications do not establish comparative clinical efficacy or superiority of either preparation for Oligozoospermia. Controlled, prospectively registered research with standardized semen analyses and reproductive outcomes is required.
Download Article
Full Article (PDF)
Download the complete article in PDF format
Full Article PDF
Download Full Text PDF
Save this article to your device for offline reading
Conflicts of Interest
The authors declare no conflict of interest.